» Articles » PMID: 33889318

Experimental Therapies Under Investigation for COVID-19

Overview
Date 2021 Apr 23
PMID 33889318
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus Disease 2019, caused by the virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is a pandemic first discovered in Wuhan, China which has claimed over 1.7 million lives to date across the globe as of 24 December 2020. As the virus spreads across the world affecting millions of patients, there has been a massive movement to discover readily available and effective treatment options including vaccines. One of the limiting factors in treating the disease is its varied presentation and effect in patients, ranging from asymptomatic patients to those left in intensive care units, intubated and fighting for their lives. There are numerous clinical trials and small-scale studies underway to investigate potential treatment options. However, very few studies and drugs demonstrated efficacy while many more are under investigation, leaving care teams dependent on supportive care coupled with experimental treatment options. In this review, we summarize the various treatment options explored to treat COVID-19, discussing possible the mechanisms of fighting the virus.

Citing Articles

Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters.

Almuqrin A, Alotaibi B, Aldali J, Alshalani A, AlSudais H, Aldali H BMC Infect Dis. 2024; 24(1):576.

PMID: 38862891 PMC: 11167824. DOI: 10.1186/s12879-024-09485-9.


Genomic chronicle of SARS-CoV-2: a mutational analysis with over 1 million genome sequences.

Ugurel O, Ata O, Turgut-Balik D Turk J Biol. 2021; 45(4):425-435.

PMID: 34803444 PMC: 8573839. DOI: 10.3906/biy-2106-8.

References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Richardson P, Corbellino M, Stebbing J . Baricitinib for COVID-19: a suitable treatment? - Authors' reply. Lancet Infect Dis. 2020; 20(9):1013-1014. PMC: 7271155. DOI: 10.1016/S1473-3099(20)30270-X. View

3.
Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

4.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

5.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View